Last reviewed · How we verify
Pneumococcal protein vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against pneumococcal protein antigens, preventing infection by Streptococcus pneumoniae.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against pneumococcal protein antigens, preventing infection by Streptococcus pneumoniae. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis).
At a glance
| Generic name | Pneumococcal protein vaccine |
|---|---|
| Also known as | pneumococcal common protein vaccine |
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The pneumococcal protein vaccine contains recombinant or purified protein antigens from Streptococcus pneumoniae that trigger both humoral (antibody) and cell-mediated immune responses. By priming the adaptive immune system to recognize pneumococcal proteins, the vaccine enables rapid immune clearance upon exposure to the pathogen, reducing disease incidence and severity.
Approved indications
- Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis)
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (PHASE2, PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: